Regulus Therapeutics (RGLS) Misses Q1 EPS by 7c

Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Worthington Enterprises raises dividend 5%, adds board member
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks